Kaleido Biosciences (NASDAQ:KLDO) Stock Price Up 6.4%

Shares of Kaleido Biosciences Inc (NASDAQ:KLDO) rose 6.4% on Tuesday . The company traded as high as $7.85 and last traded at $7.44, approximately 124,900 shares were traded during trading. An increase of 87% from the average daily volume of 66,760 shares. The stock had previously closed at $6.99.

KLDO has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of Kaleido Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 29th. Chardan Capital restated a “buy” rating on shares of Kaleido Biosciences in a research note on Thursday, September 19th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Kaleido Biosciences presently has an average rating of “Buy” and a consensus target price of $17.70.

The stock has a fifty day moving average of $6.37 and a 200-day moving average of $9.88.

Kaleido Biosciences (NASDAQ:KLDO) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.15. As a group, research analysts predict that Kaleido Biosciences Inc will post -3.58 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC acquired a new position in Kaleido Biosciences in the second quarter valued at approximately $56,000. First Trust Advisors LP acquired a new position in Kaleido Biosciences in the third quarter valued at approximately $92,000. Northern Trust Corp acquired a new position in Kaleido Biosciences in the second quarter valued at approximately $145,000. Menta Capital LLC acquired a new position in Kaleido Biosciences in the second quarter valued at approximately $164,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Kaleido Biosciences in the second quarter valued at approximately $353,000. 78.97% of the stock is owned by hedge funds and other institutional investors.

About Kaleido Biosciences (NASDAQ:KLDO)

Kaleido BioSciences, Inc develops microbiome metabolic therapies. It offers treatment for hyperammonemia, a metabolic condition generally characterized by elevated levels of ammonia in the blood; infections caused by multi-drug resistant bacteria; chronic kidney disease; atherosclerotic cardiovascular disease; and drug or disease induced diarrhea.

Read More: Book Value Per Share in Stock Trading

Receive News & Ratings for Kaleido Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kaleido Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.